Skip to content

US · SGP · BIOTECHNOLOGY

SpyGlass Pharma, Inc. Common Stock (SGP) intrinsic value and stock valuation

$30.43as of 2026-11-21 · Mkt cap 846.2M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SpyGlass Pharma, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values SGP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SGP’s statements →

SpyGlass Pharma, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Aliso Viejo, CA 92656 spyglasspharma.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$0.00
20252025
Net income
-$-39.87M
20252025
Free cash flow
-$-33.49M
20252025
Total equity
-$-98.84M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$0.00
Operating income-$-41.45M
Net income-$-39.87M
EPSd-$-1.19M
Operating cash flow-$-32.7M
Capital expenditure-$-790K
Free cash flow-$-33.49M
Total assets$115.9M
Total debt$1.58M
Net debt-$-94.78M
Total equity-$-98.84M
Cash and short-term investments$107.4M
Income statement
2025
Revenue$0.00
Cost of revenue$610K
Gross profit-$-610K
Research and development expenses$28.6M
Selling, general and administrative expenses$12.2M
Other expenses$0.00
Operating expenses$40.8M
Cost and expenses$41.5M
Interest income$3.11M
Interest expense$0.00
Depreciation and amortization$610K
Ebitda-$-39.26M
Operating income-$-41.45M
Total other income/expenses, net$1.58M
Income before tax-$-39.87M
Income tax expense$0.00
Net income-$-39.87M
Weighted average shares outstanding$33.4M
Weighted average diluted shares outstanding$33.4M
Balance sheet
2025
Cash and short-term investments$107.4M
Net receivables$430K
Inventory$0.00
Total current assets$108.8M
Property, plant and equipment, net$3.89M
Goodwill and intangible assets$0.00
Long-term investments$0.00
Total non-current assets$7.1M
Total assets$115.9M
Accounts payable$2.7M
Short-term debt$0.00
Deferred revenue$0.00
Total current liabilities$8.58M
Long-term debt$1.58M
Deferred revenue, non-current$0.00
Total non-current liabilities$206.1M
Capital lease obligations$1.58M
Total liabilities$214.7M
Common stock$0.00
Retained earnings-$-104.73M
Accumulated other comprehensive income (loss)$0.00
Total equity-$-98.84M
Total investments$11.1M
Total debt$1.58M
Net debt-$-94.78M
Cash flow statement
2025
Net income-$-39.87M
Depreciation and amortization$610K
Stock-based compensation$2.79M
Change in working capital$2.45M
Accounts receivable-$-10K
Inventory$0.00
Accounts payable$550K
Net cash provided by operating activities-$-32.7M
Investments in property, plant and equipment-$-790K
Acquisitions, net$0.00
Net cash used for investing activities-$-11.79M
Common stock issued$170K
Common stock repurchased-$-1.45M
Dividends paid$0.00
Net cash used for financing activities$124.6M
Net change in cash$80.1M
Cash at end of period$96.4M
Operating cash flow-$-32.7M
Capital expenditure-$-790K
Free cash flow-$-33.49M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SpyGlass Pharma, Inc. Common Stock

        SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

        CEO
        Patrick H. Mooney
        Employees
        68
        Beta
        -1.01

        Explore

        Frequently asked questions

        What is the intrinsic value of SpyGlass Pharma, Inc. Common Stock (SGP)?

        InvestorsCraft does not currently publish an intrinsic value for SGP. How the IC value is calculated.

        Is SGP undervalued?

        InvestorsCraft does not publish an undervaluation signal for SGP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.